Acorda Therapeutics Inc. $ACOR reported mixed fiscal third quarter results. For the quarter, revenue was $135.61 million, a drop of 8.5%, Y-o-Y, beating estimates by $1.6 million. EPS was $0.04, falling short of the guidance by $0.15. The company�s lead product, AMPYRA��(dalfampridine) 3Q 2016 net revenue was $128.8 Million; 10% Increase over 3Q 2015.It said data for Dalfampridine in Post-Stroke walking difficulties will be submitted by Year end 2016 and Phase 3 data for CVT-301 for OFF Periods in Parkinson �s disease in Q1 2017. �Over the next 12 months, we expect multiple, potentially transformative clinical and corporate milestones,� said�Ron Cohen, M.D. �By year end we plan to announce topline data from our dalfampridine post-stroke walking difficulties and QD formulation studies and, in the first quarter of 2017, data from our Phase 3 CVT-301 program�, Cohen said.